For some, being a patient means access to the best doctors and hospitals. For others, it means a courageous battle against a chronic, and perhaps incurable disease. For many, it means struggling with how to pay their bills.
In Pennsylvania, one million people are saddled with medical debt. This medical debt disproportionately impacts rural and minoritized communities, many of which are under-resourced.
A federal drug discount program called 340B, created in 1992, is the second largest drug program in the country. It was designed to help reduce the financial burden of accessing medication for the uninsured and under-insured.
However, the system has been misused. It has morphed into a way for large tax-exempt hospitals and for-profit chain pharmacies to mark up medicine prices and boost their profits.
Not working
In this program, manufacturers sell drugs to 340B hospitals at deeply discounted prices. The hospitals then contract with pharmacies to dispense those medicines. The intent was that the contracted pharmacies would be located in low resource areas and pass along the discounts to their uninsured and under-insured consumer base.
There is little evidence, however, that this program is operating in the manner it was designed. In fact, a comprehensive analysis found that most patients received “zero or close to zero” discount on the price of their drugs, even though those treatments were purchased at steep discounts through the program.
In 2022 alone, hospitals and big chain pharmacies pocketed more than $50 billion in discounts that were intended for patients.
While some 340B participants, such as community health centers and other safety-net clinics, reinvest income from the 340B program back into patient care as required by federal law, other program participants lack transparency into how, or if, savings are helping low-income patients.
Not transparent
Because of a lack of oversight and transparency within the 340B program, hospitals have gotten away contracting primarily with big chain pharmacies in wealthier, whiter neighborhoods and out of state, where customers have private insurance and pay full price.
The top five 340B pharmacies with the most contracts in Pennsylvania are owned by for-profit pharmacy benefit managers (PBMs) and big chain drug stores.
According to government data from the Health Resources and Services Administration (HRSA), the 68 hospitals in this state that are part of the 340B program have 2,250 contracts with pharmacies nationwide. Nearly one thousand of those are located out of state, including places like Hawaii and California.
Clearly, they are not in the rural communities of Pennsylvania that are home to more than a quarter of the state’s population, many of whom live on fixed incomes and cannot pay huge markups.
The 340B program has gotten so out of hand that a federal appeals court in Philadelphia took issue with the Department of Health and Human Services allowing for hospitals to contract with an unlimited number of pharmacies.
The fix
Any fix must include stipulations as to how and where the discounted drugs can be sold and to whom. There needs to be more transparency and accountability down the distribution chain, so that our most vulnerable populations are able to get the medications they need at the cost they can afford.
It’s a federal program, and only our Congressional lawmakers can lead the charge to increase regulations on 340B contracts.
The 340B program has the unique opportunity to advance health equity by supporting safety-net providers in underserved communities. Misguided eligibility standards and loopholes have allowed 340B hospitals and their associated pharmacies to prioritize profits over patients.
It is time to ensure that this gaming of the system stops and that those who the program was intended to help, are indeed being supported.
Haley Director, a member of the board of directors for Rare New England, which serves the rare disease community, is pursuing her Ph.D. at the University of Pittsburgh School of Public Health.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.